Literature DB >> 31004022

ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients.

David Sibon1, Dinh-Phong Nguyen2, Norbert Schmitz3, Ritsuro Suzuki4, Andrew L Feldman5, Rémy Gressin6, Laurence Lamant7, Dennis D Weisenburger8, Andreas Rosenwald9, Shigeo Nakamura10, Marita Ziepert11, Matthew J Maurer12, Martin Bast13, James O Armitage13, Julie M Vose13, Hervé Tilly14, Jean-Philippe Jais2, Kerry J Savage15.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31004022      PMCID: PMC6959172          DOI: 10.3324/haematol.2018.213512

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.

Authors:  Henrik Cederleuf; Martin Bjerregård Pedersen; Mats Jerkeman; Thomas Relander; Francesco d'Amore; Fredrik Ellin
Journal:  Br J Haematol       Date:  2017-05-08       Impact factor: 6.998

Review 2.  The biology and management of systemic anaplastic large cell lymphoma.

Authors:  Greg Hapgood; Kerry J Savage
Journal:  Blood       Date:  2015-04-13       Impact factor: 22.113

3.  Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.

Authors:  R Suzuki; Y Kagami; K Takeuchi; M Kami; M Okamoto; R Ichinohasama; N Mori; M Kojima; T Yoshino; H Yamabe; M Shiota; S Mori; M Ogura; N Hamajima; M Seto; T Suchi; Y Morishima; S Nakamura
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

4.  Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network.

Authors:  Camille Laurent; Marine Baron; Nadia Amara; Corinne Haioun; Mylène Dandoit; Marc Maynadié; Marie Parrens; Beatrice Vergier; Christiane Copie-Bergman; Bettina Fabiani; Alexandra Traverse-Glehen; Nicole Brousse; Marie-Christine Copin; Patrick Tas; Tony Petrella; Marie-Christine Rousselet; Josette Brière; Fréderic Charlotte; Catherine Chassagne-Clement; Thérèse Rousset; Luc Xerri; Anne Moreau; Antoine Martin; Diane Damotte; Peggy Dartigues; Isabelle Soubeyran; Michel Peoch; Pierre Dechelotte; Jean-François Michiels; Antoine de Mascarel; Françoise Berger; Céline Bossard; Flavie Arbion; Isabelle Quintin-Roué; Jean-Michel Picquenot; Martine Patey; Blandine Fabre; Henri Sevestre; Cécile Le Naoures; Marie-Pierre Chenard-Neu; Claire Bastien; Sylvie Thiebault; Laurent Martin; Manuela Delage; Thomas Filleron; Gilles Salles; Thierry Jo Molina; Georges Delsol; Pierre Brousset; Philippe Gaulard
Journal:  J Clin Oncol       Date:  2017-05-01       Impact factor: 44.544

5.  Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group.

Authors:  Norbert Schmitz; Lorenz Trümper; Marita Ziepert; Maike Nickelsen; Anthony D Ho; Bernd Metzner; Norma Peter; Markus Loeffler; Andreas Rosenwald; Michael Pfreundschuh
Journal:  Blood       Date:  2010-07-21       Impact factor: 22.113

6.  Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.

Authors:  Fredrik Ellin; Jenny Landström; Mats Jerkeman; Thomas Relander
Journal:  Blood       Date:  2014-07-08       Impact factor: 22.113

7.  ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.

Authors:  Edgardo R Parrilla Castellar; Elaine S Jaffe; Jonathan W Said; Steven H Swerdlow; Rhett P Ketterling; Ryan A Knudson; Jagmohan S Sidhu; Eric D Hsi; Shridevi Karikehalli; Liuyan Jiang; George Vasmatzis; Sarah E Gibson; Sarah Ondrejka; Alina Nicolae; Karen L Grogg; Cristine Allmer; Kay M Ristow; Wyndham H Wilson; William R Macon; Mark E Law; James R Cerhan; Thomas M Habermann; Stephen M Ansell; Ahmet Dogan; Matthew J Maurer; Andrew L Feldman
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

8.  Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.

Authors:  Barbara Pro; Ranjana Advani; Pauline Brice; Nancy L Bartlett; Joseph D Rosenblatt; Tim Illidge; Jeffrey Matous; Radhakrishnan Ramchandren; Michelle Fanale; Joseph M Connors; Keenan Fenton; Dirk Huebner; Juan M Pinelli; Dana A Kennedy; Andrei Shustov
Journal:  Blood       Date:  2017-10-03       Impact factor: 22.113

Review 9.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.

Authors:  N L Harris; E S Jaffe; H Stein; P M Banks; J K Chan; M L Cleary; G Delsol; C De Wolf-Peeters; B Falini; K C Gatter
Journal:  Blood       Date:  1994-09-01       Impact factor: 22.113

10.  Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study.

Authors:  Carlo Gambacorti-Passerini; Sergey Orlov; Li Zhang; Fadi Braiteh; Huiqiang Huang; Taito Esaki; Keizo Horibe; Jin-Seok Ahn; Joseph T Beck; William Jeffrey Edenfield; Yuankai Shi; Matthew Taylor; Kenji Tamura; Brian A Van Tine; Shang-Ju Wu; Jolanda Paolini; Paulina Selaru; Tae Min Kim
Journal:  Am J Hematol       Date:  2018-02-08       Impact factor: 10.047

View more
  5 in total

Review 1.  Peripheral T-Cell Lymphomas: Therapeutic Approaches.

Authors:  David Sibon
Journal:  Cancers (Basel)       Date:  2022-05-08       Impact factor: 6.575

Review 2.  NPM-ALK: A Driver of Lymphoma Pathogenesis and a Therapeutic Target.

Authors:  Elissa Andraos; Joséphine Dignac; Fabienne Meggetto
Journal:  Cancers (Basel)       Date:  2021-01-05       Impact factor: 6.639

3.  De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells.

Authors:  Loélia Babin; Alice Darchen; Elie Robert; Zakia Aid; Rosalie Borry; Claire Soudais; Marion Piganeau; Anne De Cian; Carine Giovannangeli; Olivia Bawa; Charlotte Rigaud; Jean-Yves Scoazec; Lucile Couronné; Layla Veleanu; Agata Cieslak; Vahid Asnafi; David Sibon; Laurence Lamant; Fabienne Meggetto; Thomas Mercher; Erika Brunet
Journal:  Mol Cancer       Date:  2022-03-04       Impact factor: 27.401

Review 4.  Anaplastic Large Cell Lymphoma: Molecular Pathogenesis and Treatment.

Authors:  Xin-Rui Zhang; Pham-Ngoc Chien; Sun-Young Nam; Chan-Yeong Heo
Journal:  Cancers (Basel)       Date:  2022-03-24       Impact factor: 6.639

Review 5.  From circRNAs to fusion circRNAs in hematological malignancies.

Authors:  Loelia Babin; Elissa Andraos; Steffen Fuchs; Stéphane Pyronnet; Erika Brunet; Fabienne Meggetto
Journal:  JCI Insight       Date:  2021-11-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.